文献速递脑血管病

CYP2C19基因型与缺血性卒中24至72小时启动氯吡格雷的疗效

CYP2C19 Genotype and Efficacy of Clopidogrel Initiated Between 24 to 72 Hours for Ischemic Stroke.
PubMed 文献 · Stroke · 2025-09-18

该研究为INSPIRES试验预设二次分析,纳入5003例轻卒中或TIA患者,比较发病24-72小时启动氯吡格雷-阿司匹林与单用阿司匹林的效果。结果显示,在CYP2C19功能缺失等位基因非携带者中,氯吡格雷-阿司匹林降低90天新发卒中风险(HR 0.67,95%CI 0.49-0.91,P=0.01),携带者中无显著获益(HR 0.96,95%CI 0.73-1.25,P=0.74)。

要点

  • CYP2C19功能缺失非携带者24-72小时启动氯吡格雷-阿司匹林可降低新发卒中风险
  • CYP2C19功能缺失携带者未观察到显著获益
  • 支持在延长至72小时的治疗窗内进行CYP2C19基因分型以指导抗血小板选择

核心结论

  • 在发病24-72小时内启动氯吡格雷-阿司匹林治疗,CYP2C19功能缺失非携带者较单用阿司匹林降低90天新发卒中风险,携带者无显著获益。

研究设计与样本

  • 共纳入5003例发病24-72小时启动治疗的轻卒中或TIA患者,其中CYP2C19功能缺失携带者2911例(58.2%),非携带者2092例(41.8%)。
  • 所有患者随机接受氯吡格雷-阿司匹林或阿司匹林治疗,主要疗效结局为90天内新发卒中,主要安全结局为中重度出血。

主要发现

  • 非携带者中,氯吡格雷-阿司匹林较单用阿司匹林降低新发卒中率(HR 0.67,95%CI 0.49-0.91,P=0.01)。
  • 携带者中,氯吡格雷-阿司匹林与单用阿司匹林的新发卒中率无显著差异(HR 0.96,95%CI 0.73-1.25,P=0.74;交互作用P=0.09)。
  • 中重度出血在携带者(HR 1.83,95%CI 0.68-4.95,P=0.23)和非携带者(HR 2.07,95%CI 0.62-6.88,P=0.23;交互作用P=0.88)中均无显著差异。

关键数值与推荐

  • CYP2C19功能缺失等位基因定义为携带CYP2C19*2或CYP2C19*3。
  • 主要疗效结局为90天内新发卒中,主要安全结局为中重度出血。
  • 采用Cox比例风险模型估计治疗分组与CYP2C19功能缺失状态的交互作用。

临床怎么用

  • 对于发病24-72小时的轻卒中或TIA患者,可根据CYP2C19基因型选择抗血小板策略:非携带者优先考虑氯吡格雷-阿司匹林,携带者可能需替代方案。
  • 研究结果支持将CYP2C19基因分型用于指导抗血小板治疗,并将治疗窗延长至72小时。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The aim of this study was to investigate the clinical outcomes of clopidogrel-aspirin therapy initiated between 24 and 72 hours from the symptom onset among patients with minor stroke or transient ischemic attack stratified by CYP2C19 loss-of-function allele status. METHODS: This was a prespecified secondary analysis of the INSPIRES trial (Intensive Statin and Antiplatelet Therapy for Acute High-Risk Intracranial or Extracranial Atherosclerosis), which was a randomized clinical trial conducted across 222 centers in China from September 2018 to October 2022. Two loss-of-function alleles (CYP2C19*2, CYP2C19*3) and 1 gain-of-function allele (CYP2C19*17) were genotyped in the INSPIRES study. Patients with CYP2C19 loss-of-function allele carriers were patients with either CYP2C19*2 or CYP2C19*3. All participants were randomized to receive clopidogrel-aspirin or aspirin treatment, and those started treatment between 24 and 72 hours from the symptom onset were included in this study. The primary efficacy outcome was new stroke within 90 days. The primary safety outcome was moderate-to-severe bleeding. Cox proportional hazards models were performed to estimate the interaction between treatment assignment and CYP2C19 loss-of-function allele status for the primary outcomes. RESULTS: Among 5003 patients, 2911 (58.2%) patients were loss-of-function carriers, and 2092 (41.8%) patients were noncarriers. Relative to aspirin alone, clopidogrel-aspirin reduced the rate of new stroke in the noncarriers (hazard ratio, 0.67 [95% CI, 0.49-0.91]; P=0.01) but not in the carriers (hazard ratio, 0.96 [95% CI, 0.73-1.25], P=0.74; P=0.09 for interaction). For the safety outcome, moderate-to-severe bleeding did not vary significantly between the carriers (hazard ratio, 1.83 [95% CI, 0.68-4.95]; P=0.23) and noncarriers (hazard ratio, 2.07 [95% CI, 0.62-6.88], P=0.23; P=0.88 for interaction). CONCLUSIONS: Clopidogrel-aspirin treatment presented a priority to aspirin in reducing the risk of new stroke in CYP2C19 loss-of-function noncarriers when administered between 24 and 72 hours after stroke onset. These findings supported the necessity of CYP2C19 genotyping in the choice of antiplatelet therapy with an extended treatment window to 72 hours. REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT03635749.

来源:Stroke,查看原文。版权归原作者所有。

引用

  1. Chen Y, Jiang L, Gao Y, et al. CYP2C19 Genotype and Efficacy of Clopidogrel Initiated Between 24 to 72 Hours for Ischemic Stroke. Stroke. 2025. PMID: 40964718. doi:10.1161/STROKEAHA.125.052167

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。